
Setting the bar higher for KRAS inhibitors - pleased to share our study of divarasib in KRAS G12C lung/colon/solid tumors in @NEJM. Impressive response rate, durability and tolerability. Thanks to pts and co-investigators. @KRASKickers #lcsm
Among patients with cancers bearing the KRAS G12C mutation who received divarasib at a 400-mg dose, 56% with lung cancer, 36% with colorectal cancer, and 36% with other tumor types had a confirmed response. 🔗 Read the full study results: nej.md/45xZYok #oncology


































